Dr Hugh Leslie — ArticlesEvidence-based longevity medicine for people who want to live better, longer.https://drhughleslie.com.au/ApoB, LDL and Cardiovascular Risk — Looking Beyond the Standard Cholesterol Testhttps://drhughleslie.com.au/articles/apob-ldl-cardiovascular-risk/https://drhughleslie.com.au/articles/apob-ldl-cardiovascular-risk/Standard cholesterol tests are useful, but they do not always show the full picture. ApoB can provide a clearer measure of the number of atherogenic particles driving cardiovascular risk.Wed, 29 Apr 2026 00:00:00 GMTBiological Age Testing — Useful Signal or Marketing Noise?https://drhughleslie.com.au/articles/biological-age-testing/https://drhughleslie.com.au/articles/biological-age-testing/Biological age tests are increasingly popular, but their clinical value is often overstated. They may provide interesting signals, but they should not be confused with a diagnosis or a complete measure of health.Wed, 29 Apr 2026 00:00:00 GMTBlood Pressure and Brain Ageing — Why Midlife Control Mattershttps://drhughleslie.com.au/articles/blood-pressure-brain-ageing/https://drhughleslie.com.au/articles/blood-pressure-brain-ageing/Blood pressure is not only a heart issue. Midlife hypertension can affect the brain's small vessels, increasing the long-term risk of cognitive decline, stroke and loss of independence.Wed, 29 Apr 2026 00:00:00 GMTGLP-1 Medications and Healthspan — Beyond Weight Losshttps://drhughleslie.com.au/articles/glp-1-medications-healthspan/https://drhughleslie.com.au/articles/glp-1-medications-healthspan/GLP-1 medications are best known for weight loss, but their relevance to healthspan is broader. Their value depends on careful patient selection, monitoring and long-term clinical context.Wed, 29 Apr 2026 00:00:00 GMTRapamycin and Longevity — History, Evidence and the Human Trial Questionhttps://drhughleslie.com.au/articles/rapamycin-longevity/https://drhughleslie.com.au/articles/rapamycin-longevity/Rapamycin is one of the most important drugs in ageing biology, with strong animal data and growing human interest. The key question is whether its effects on mTOR can translate into meaningful healthspan benefits in people.Wed, 29 Apr 2026 00:00:00 GMTZone 2 Training and Metabolic Health — Why Easy Exercise Is Not Wasted Exercisehttps://drhughleslie.com.au/articles/zone-2-training-metabolic-health/https://drhughleslie.com.au/articles/zone-2-training-metabolic-health/Not every workout needs to be hard. Zone 2 training builds aerobic capacity, improves metabolic flexibility and supports long-term health in a way that high-intensity exercise alone cannot.Wed, 29 Apr 2026 00:00:00 GMTSleep Architecture and Healthspan — Why Quality Matters as Much as Quantityhttps://drhughleslie.com.au/articles/sleep-architecture-healthspan/https://drhughleslie.com.au/articles/sleep-architecture-healthspan/Eight hours in bed is not the same as eight hours of restorative sleep. Understanding sleep architecture changes how we think about optimising sleep for long-term health.Mon, 20 Jan 2025 00:00:00 GMTSupplements — What the Evidence Actually Showshttps://drhughleslie.com.au/articles/supplements-what-evidence-shows/https://drhughleslie.com.au/articles/supplements-what-evidence-shows/The supplement industry generates billions annually on promises of better health and longer life. Most products are not supported by robust evidence. A few are. Here is how to tell the difference.Sun, 05 Jan 2025 00:00:00 GMT